Menu
Search
|

Menu

Close
X

Eloxx Pharmaceuticals Inc ELOX.OQ (NASDAQ Stock Exchange Global Market)

12.71 USD
+0.78 (+6.54%)
As of Feb 15
chart
Previous Close 11.93
Open 12.00
Volume 33,163
3m Avg Volume 22,423
Today’s High 13.06
Today’s Low 11.67
52 Week High 24.60
52 Week Low 9.31
Shares Outstanding (mil) 35.12
Market Capitalization (mil) 446.44
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.019
FY17
-8.674
FY16
-8.278
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.99
Price to Sales (TTM)
vs sector
--
10.11
Price to Book (MRQ)
vs sector
8.67
4.60
Price to Cash Flow (TTM)
vs sector
--
26.60
Total Debt to Equity (MRQ)
vs sector
0.00
16.95
LT Debt to Equity (MRQ)
vs sector
0.00
13.45
Return on Investment (TTM)
vs sector
-172.13
12.72
Return on Equity (TTM)
vs sector
-186.05
13.73

EXECUTIVE LEADERSHIP

Robert Ward
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Gregory Weaver
Chief Financial Officer, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Gregory Williams
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Neil Belloff
Executive Vice President, General Counsel, Corporate Secretary, Since 2018
Salary: --
Bonus: --
Pedro Huertas
Chief Medical Officer, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

950 Winter St
WALTHAM   MA   02451-1424

Phone: +1858.9090749

Eloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. The Company’s lead product candidate is ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. The ELX-02, which is in Phase I clinical trial that focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. As part of clinical program, the Company has completed a Phase Ia single ascending dose study in Israel and Belgium. The Company also intends to advance one or more additional molecules from its drug product candidate library toward clinical development.

SPONSORED STORIES